Thiopurines [e.g. mercaptopurine (MP)] are widely used as chemotherapeutic agents in the treatment of pediatric acute lymphoblastic leukemia with dose-limiting hematopoietic toxicity. Recently, germline variants in NUDT15 have been identified as a major genetic cause for MP-related bone marrow suppression, and there is increasing interest in the clinical implementation of NUDT15 genotype-guided MP dose individualization. Therefore, we sought to evaluate the effects of NUDT15 on thiopurine metabolism and identify pharmacologic markers to inform NUDT15 genotype-guided MP dosing. In 55 Japanese children with acute lymphoblastic leukemia, we simultaneously measured both thioguanine nucleotides (TGN) in red blood cells and DNAincorporated thioguanine (DNA-TG) in white blood cells. TGN levels were significantly lower in patients with NUDT15 deficiency, likely because of toxicity-related MP dose reduction. In contrast, when exposed to the same dose of MP, DNA-TG accumulated more efficiently in vivo with increasing number of risk alleles in NUDT15 (P = 4.0 × 10 − 9
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Introduction
Thiopurines [e.g. 6-mercaptopurine (MP)] are widely used purine antimetabolites [1, 2] . In acute lymphoblastic leukemia (ALL), patients are exposed to daily MP for more than a year to achieve a long-term cure [3] [4] [5] [6] . However, frequent MP dose adjustment is needed because of severe myelosuppression that can lead to lifethreatening infections [3] . Thiopurines are prodrugs that require enzymatic conversion into thioguanine nucleotides (TGN), which are in turn incorporated into DNA (forming DNA-TG) to induce cell apoptosis [1] . Therefore, active metabolites of thiopurines (i.e. TGN and DNA-TG) are hypothesized to be the pharmacologic determinants of drug efficacy and toxicity. Previous studies have reported that thiopurine toxicity can be influenced by inherited genetic polymorphisms in the TPMT and NUDT15 genes, which encode key enzymes involved in thiopurine metabolism, particularly the formation of TGN and DNA-TG, respectively [7] [8] [9] [10] [11] [12] .
Pre-emptive TPMT-guided thiopurine dose adjustments have been clinically implemented to mitigate drug toxicity as a prototype of pharmacogenetics-driven precision medicine [13] [14] [15] . However, the TPMT-based algorithm is not universally informative because TPMT risk alleles are uncommon in certain ancestral groups (e.g. East Asians). In contrast, NUDT15 variants are the primary genetic cause for thiopurine toxicity in Asians and Hispanics for whom NUDT15-based dosing can be of particular relevance. In fact, in the Japanese population, one in every four individuals carries at least one copy of the known damaging alleles in NUDT15 and one in every 50 individuals is homozygous or compound heterozygous for these defective variants. When thiopurine dosing is adjusted on the basis of the TPMT genotype, the premise is to decrease thiopurine dose for patients with TPMT deficiency such that they are exposed to a TGN level comparable with that in patients with wild-type alleles who receive the standard thiopurine dose. Although we hypothesized that this principle could be adopted for MP dose reduction in patients with NUDT15 risk alleles [12, 16] , it remains unclear which MP metabolites should be monitored to direct dose modification. Here, as a part of the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) ALL B-12 protocol, we simultaneously determined TGN and DNA-TG during MP therapy, and evaluate the effects of NUDT15 genotype on these metabolites.
Patients and therapy
A total of 55 pediatric patients with newly diagnosed ALL and treated on standard-risk (N = 47), intermediaterisk (N = 7), or high-risk arms (N = 1) of the JPLSG ALL B-12 protocol (http://www.umin.ac.jp, UMIN000009339) were included in this study. Of these, 32 were described previously [12] . The standard MP dosage during the maintenance phase of treatment was 50 mg/m 2 /day and the dosage was adjusted to a target white blood cell (WBC) count of between 2.0 × 10 9 and 3.0 × 10 9 cells/l according to a standardized guideline in the ALL B-12 protocol. Peripheral blood collection was scheduled for the 13th and 41st weeks after the initiation of maintenance therapy and all patients in this study received at least 14 days of MP at a stable dose before blood draw. The 14-day average dosage was used to define MP tolerance (i.e. the tolerated MP dosage). Patients were selected on the basis of the availability of germline DNA, thiopurine metabolite data, and MP dosage history (i.e. at least 14 days of stable MP dosage at the time of sample collection). This study was approved by the respective institutional review boards and informed consent was obtained from the parents, guardians, and/or patients, as appropriate.
NUDT15 and TPMT genotyping
Germline DNA was extracted from peripheral blood collected in EDTA tubes from patients who were in clinical remission. Coding regions (exons 1, 2, and 3) of the NUDT15 gene were first amplified by PCR from germline DNA, and then Sanger sequencing was performed as described previously [12] . Sequence alignment and comparison were performed using the CLC Genomics Workbench (CLC Bio; Qiagen, Redwood City, California, USA) to identify genetic variants. Common TPMT risk variants (rs1800462, rs1800460, and rs1142345, defining the *2, *3A, *3B, and *3C alleles) were genotyped using Sanger sequencing [17] .
Quantification of leukocyte DNA-TG and erythrocyte TGN DNA was extracted from nucleated cells in peripheral blood within 72 h of blood collection. The levels of DNA-TG were quantified using liquid chromatography-mass spectrometry/mass spectrometry as described in previous reports [16, [18] [19] [20] . The stability of DNA-TG was evaluated and we observed no significant variation within the 72 h window. Erythrocyte TGN was quantified in the hydrolyzed cell lysate using high-performance liquid chromatography [21] .
Statistical analysis
Each patient was assigned a NUDT15 'genetic score' of 0, 1, or 2, indicating normal, intermediate, or low NUDT15 activity, respectively, on the basis of four known nonfunctional variants [12] . The correlation between the NUDT15 genetic score and MP tolerance and thiopurine metabolites (TGN, TGN/dosage, DNA-TG/dosage, and DNA-TG/TGN) was tested using the linear regression model. Correlation between TGN and DNA-TG was determined using the Spearman rank test. All statistical tests were two sided and were chosen as appropriate according to the data distribution; the threshold for statistical significance was defined as a P-value less than 0.05. In the majority of patients, MP dosage and metabolite levels were measured at more than one time points for each patient and these values were included in the analyses as independent measurements. We also tested the genotype-phenotype association after assigning an MP dosage and metabolite value for each patient using the average of values from multiple time points, and observed similar results. R software (version 3.0; http:// www.r-project.org/ ) was used for all analyses unless indicated otherwise.
Results
A total of 55 children enrolled on the JPLSG B-12 frontline ALL protocol were included in this study and 74 peripheral blood samples (1.3/patient) were collected for measurement of thiopurine metabolites (TGN and DNA-TG) during daily MP treatment as part of the maintenance therapy ( Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved. ) and this association remained significant after adjusting for MP dosage (P = 1.7 × 10 − 6 ). In contrast, patients with the low-activity NUDT15 diplotypes had the highest DNA-TG/dosage ratio, followed by the intermediate-activity diplotype group, and the lowest in patients with wild-type NUDT15 (P = 4.0 × 10
). Importantly, we observed that cytosolic TGN and nuclear DNA-TG levels were highly correlated with each other, consistent with the fact that TGN is the precursor metabolite of DNA-TG during thiopurine activation (P = 6.5 × 10 Fig. 1 ). However, the regression slope of DNA-TG over TGN was significantly higher for patients with the intermediate-activity NUDT15 diplotype (the dotted line) than those with the normal-activity NUDT15 diplotype (the solid line in Fig. 1) . Consistently, the ratio of DNA-TG to TGN (i.e. the percent of TGN converted to DNA-TG) was significantly higher in NUDT15-deficient patients (P = 3.6 × 10 − 9 , Fig. 2) , suggesting that the lack of functional NUDT15 directly resulted in more robust conversion of TGN into DNA-TG, and therefore increased risk of toxicity.
Discussion
It is now well established that NUDT15 is a major negative regulator of thiopurine activation and polymorphisms in this gene strongly influence hematopoietic toxicity related to this class of drugs [10] [11] [12] 22, 23] . Therefore, there is a pressing need to develop an NUDT15-based dosing algorithm to individualize thiopurine therapy. To this end, we aimed to evaluate how NUDT15 genotype affects two main active metabolites of thiopurines (TGN and DNA-TG) in a cohort of Japanese pediatric ALL patients. In patients with TPMT deficiency, because thiopurines cannot be inactivated by methylation, the prodrug is converted into TGN in excess. In fact, despite 90% dose reduction, the TGN level remains significantly higher in patients with homozygous TPMT deficiency compared with those with wild-type TPMT receiving a full dose of thiopurine [24] . In contrast, the absolute level of TGN was significantly lower in patients with NUDT15 risk variants, most likely reflecting the reduced dose received. This is consistent with our previous report that the point of action of NUDT15 is distinct from TPMT in thiopurine metabolism pathway, and also suggests that TGN is not responsible for the excessive toxicity in patients with NUDT15 deficiency [12] . Instead, NUDT15 alters the ratio of TGTP to TGMP (but not the total TGN), which in turn increases thioguanine incorporation into DNA (DNA-TG) in deficient patients, as shown in our previous studies in vitro [12] . If this holds true in patients, cytosolic TGTP and nuclear DNA-TG in WBC would be the most relevant metabolite to be monitored in patients with NUDT15 deficiency. This strategy has a number of potential advantages over the current erythrocyte TGN Association of erythrocyte TGN with mononucleated cells DNA-TG. Cytosolic TGN and nuclear DNA-TG levels were highly correlated with each other, consistent with the fact that TGN is the precursor metabolite of DNA-TG during thiopurine activation (P = 6.5 × 10 − 4 , R 2 = 0.16). However, the regression slope of DNA-TG over TGN was significantly higher for patients with the intermediate-activity NUDT15 diplotype (the dotted line) than those with the normal-activity NUDT15 diplotype (the solid line). DNA-TG, DNA-incorporated thioguanine; RBC, red blood cell; TGN, thioguanine nucleotide. Association of DNA-TG/TGN with NUDT15 genotypes. The ratio of DNA-TG to TGN (i.e. the percent of TGN converted to DNA-TG) was significantly higher in NUDT15-deficient patients (P = 3.6 × 10
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assay: (a) TGTP and DNA-TG would be measured from WBC, which represent cell populations directly affected by myelosuppression, as opposed to TGN measured in RBCs as a proxy marker, (b) because TGTP and DNA-TG are more directly related to DNA damage, they are thus possibly better metabolite markers for thiopurine cytotoxicity compared with TGN. It should be noted that methylated thiopurine metabolites have also been shown directly or indirectly to influence DNA-TG conversion [20] . Finally even though there was a significant difference in the DNA-TG/TGN ratio by the NUDT15 genotype, there was also a notable variation in MP metabolites within each genotype group, pointing to possible effects of other yet unknown genetic variants.
Conclusion
Our results suggest that DNA-TG levels were strongly influenced by NUDT15 genotypes in children with ALL and point to this metabolite as a potential therapeutic drug monitoring endpoint for NUDT15 genotype-based thiopurine dosing algorithms.
